CADTH Canadian Drug Expert Committee recommendation. AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) : indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults.

CADTH Canadian Drug Expert Committee recommendation. indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults. AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) :

Show other versions (7)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults.

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK534677/
Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Muscle Spasticity > drug therapy.
Upper Extremity > physiopathology.
Botulinum Toxins, Type A > therapeutic use.
Insurance, Health, Reimbursement > economics.
Drug Costs.
Cost-Benefit Analysis.
Canada.
Search Result 5
Clinical review report. AbobotulinumtoxinA (Dysport therapeutic) : (Ipsen Biopharmaceuticals Canada, Inc.).

Clinical review report. AbobotulinumtoxinA (Dysport therapeutic) : (Ipsen Biopharmaceuticals Canada, Inc.).

Version 1.0.
Published 2017
Get full text
Full text
Electronic eBook
Save to List
Saved in:
Show all versions (8)

Similar Items